SCHEMBL31662216

SCHEMBL31662216

COCOc1cc(Cl)c(I)c(Br)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25180363 0.82 MAPT (0.31)
SCHEMBL31291676 0.81 GRM5 (0.35)
SCHEMBL31618520 0.81 SMN1; SMN2 (0.31)
SCHEMBL19617225 0.79 GRM5 (0.32)
SCHEMBL30922441 0.79 CA1 (0.40)
SCHEMBL30758972 0.78
SCHEMBL19616761 0.78 THRA (0.31)
SCHEMBL3155327 0.77 CA2 (0.40)
SCHEMBL30758963 0.77 CA2 (0.33)
SCHEMBL23043217 0.76 SOS1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304599-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-10-02 US disclosed
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed